Compare ADMA Biologics Inc (ADMA) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Kimberly Clark Corp — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Kimberly Clark Corp trades at $111.27 (market cap $38.09B). The key difference: Kimberly Clark Corp is far larger — about 17.9× ADMA Biologics Inc's market cap, and Kimberly Clark Corp pays a 4.46% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KMB | |
|---|---|---|
Market Cap | $2.13B | $38.09B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $136.77 |
52-Week Low | $7.60 | $93.05 |
Enterprise Value | $2.20B | $44.63B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Kimberly-Clark (KMB) trades at $114.74, up 0.02% on the day, showing stable performance near its consensus price target. The stock maintains a bullish technical signal with strong moving average support, though oscillators indicate potential overbought conditions. Fundamentally, the company demonstrates consistent earnings beats with Q1 2026 EPS of $1.97 exceeding expectations, supported by a healthy 12.8% net income margin and robust ROE of 146.29%. Recent corporate actions include a $1.28 dividend payment scheduled for July 2026.
KMB presents a mixed outlook with strong profitability metrics offset by revenue declines from $20.4B in 2023 to $16.45B in 2025. Investment appeal includes a 5%+ dividend yield and analyst consensus leaning toward Hold (58.06%) with a $109.20 price target. Key risks include margin pressure from input costs and competitive threats from new market entrants like Arbex. Institutional sentiment remains cautious despite technical strength, requiring monitoring of Q2 2026 earnings due August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
